TScan Therapeutics (TCRX) is a very important biotech to watch closely in the coming year. The reason why is because it is in the process of developing its T-Cell Receptor [TCR] engineered T-cell ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T ...

TScan Therapeutics Inc. (NASDAQ:TCRX), a biotechnology company specializing in T-cell receptor (TCR) therapies with a market capitalization of $102 million, is navigating a critical phase in its ...

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously ...

TScan Therapeutics' stock rises after announcing a $30 million financing deal with Lynx1, extending its cash runway into 2027. Around $10M Bet On This Real Estate Stock? Check Out These 3 Penny ...

TScan Therapeutics has a fifty-two week low of $1.71 and a fifty-two week high of $9.69. The stock has a market capitalization of $98.47 million, a P/E ratio of -1.64 and a beta of 0.91.

Morgan Stanley analyst Maxwell Skor assumed coverage of TScan Therapeutics (TCRX) with an Overweight rating and $10 price target Recent Phase 1 ALLOHA data showed product candidates TSC-100 and ...

TScan Therapeutics, Inc. WALTHAM, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell ...